Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe

Resch, G.; Schaberl-Moser, Renate; Kier, P; Kopetzky, Gerhard; Scheithauer, Werner; Sliwa, Thamer; Greil, Richard; Nösslinger, Thomas; Mayrbäurl, Beate; Thaler, Josef

doi:10.1093/annonc/mdq744

Cited by 12 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…102,103 Based on case reports and a small trial, administration of panitumumab seems to be feasible for patients experiencing severe infusion reactions to cetuximab. [106][107][108] Skin toxicity is a side effect of both of these agents and is not considered part of the infusion reactions. The incidence and severity of skin reactions with cetuximab and panitumumab seem to be very similar.…”

Section: Cetuximab and Panitumumabmentioning

confidence: 99%

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

Venook²,

Cederquist³

et al. 2017

J Natl Compr Canc Netw

752

515

View full text Add to dashboard Cite

OverviewColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2016, an estimated 95,270 new cases of colon cancer and approximately 39,220 cases of rectal cancer will occur. During the same year, an estimated 49,190 people will die of colon and rectal cancer combined. AbstractThis portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions. J Natl Compr Canc Netw 2017;15(3): 370-398 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Cetuximab and Panitumumabmentioning

confidence: 99%

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

Venook²,

Cederquist³

et al. 2017

J Natl Compr Canc Netw

752

515

View full text Add to dashboard Cite

show abstract

“…164,166 Based on case reports and a small trial, administration of panitumumab seems to be feasible for patients experiencing severe infusion reactions to cetuximab. [167][168][169] Skin toxicity is a side effect of both of these agents and is not considered part of the infusion reactions. The incidence and severity of skin reactions with cetuximab and panitumumab seems to be very similar.…”

mentioning

confidence: 99%

Colon Cancer, Version 3.2014

Benson¹,

Venook²,

Bekaii‐Saab³

et al. 2014

J Natl Compr Canc Netw

209

174

View full text Add to dashboard Cite

OverviewColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2013, an estimated 102,480 new cases of colon cancer and approximately 40,340 cases of rectal cancer will occur. During the same year, an estimated 50,830 people will die of colon and rectal cancers combined. AbstractThe NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference. (J Natl Compr Canc Netw 2014;12:1028-1059 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

“…Several case reports 23,24 and a single study 25 suggest that panitumumab is not affected by the presence of anti-cetuximab antibodies.…”

Section: Discussionmentioning

confidence: 99%

A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases

Marks

Rizvi

Sarwani

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

We present the case of a 43-year-old-man with wild-type KRAS and BRAF colorectal adenocarcinoma that was metastatic to the liver and lung. The patient initially received neoadjuvant chemotherapy with FOLFOX and bevacizumab, followed by surgical resection of the primary tumor and hepatic metastases. His disease recurred shortly after surgery and he was treated with FOLFIRI plus the anti-EGFR antibody cetuximab. After this regimen failed to arrest his disease progression, treatment with FOLFIRI in combination with another anti-EGFR antibody, panitumumab was started. While on this therapy, the patient's lung nodules remained largely stable but metastatic lesions within the liver continued to progress. Our case highlights the differences between panitumumab and cetuximab, and contemplates the possible explanations for this patient's apparently heterogeneous disease progression within the liver despite stabilization of multiple pulmonary nodules.

show abstract

Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe

Cited by 12 publications

References 6 publications

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Colon Cancer, Version 3.2014

A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases

Contact Info

Product

Resources

About